Powder -20℃ 3 years; 4℃ 2 years In solvent -80℃ 6 months;-20℃ 1 month
研究领域:
Cancer
描述:
TAK-285 is a dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.